New treatments that target the protein tau are beginning to enter human clinical trials. While tau-related therapies hold great promise for AD, clinical trials focusing on pure tauopathies are appealing because these diseases do not exhibit concurrent amyloid pathology. Pure 4 microtubule binding repeat (4R) tauopathies (4RT) include corticobasal degeneration (CBD), progressive supranuclear palsy (PSP) and some variants of frontotemporal lobar degeneration. There are no approved or effective therapies for 4RT. We designed 4RTNI to develop biomarkers of disease progression in CBD and PSP; such biomarkers may facilitate clinical trials for 4RT tauopathies.

You may be eligible for this study if you meet the following criteria:

• Conditions: ['Corticobasal Degeneration (CBD)', 'Corticobasal Syndrome (CBS)', 'Cortical-basal Ganglionic Degeneration (CBGD)', 'Progressive Supranuclear Palsy (PSP)', 'Nonfluent Variant Primary Progressive Aphasia (nfvPPA)', 'Oligosymptomatic/Variant Progressive Supranuclear Palsy (o/vPSP)']
• Age: 99 years or below
• Gender: All